Why This FDA Approval Is a Game Changer for Eli Lilly

·3 min read
Why This FDA Approval Is a Game Changer for Eli Lilly

Eli Lilly (NYSE: LLY) is a top healthcare company that continually finds new ways to grow and create value for its investors. One of the company's recent diabetes treatments has obtained approval from the U.S. Food and Drug Administration (FDA). On May 13, Eli Lilly announced that the FDA had approved Mounjaro (tirzepatide) to treat people with type 2 diabetes.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting